Evidence map›Paper›PMID 37812321›Full record

ReviewCurrent treatment options in oncology2023

Radiotherapy for Advanced Esophageal Cancer: from Palliation to Curation.

Zhuocheng Xin, Qi Liu, Dashan Ai, Ke Chen, Elene Mariamidze, Mostafa Aziz Sumon, Bharti Devnani, Rille Pihlak, Hongcheng Zhu, Kuaile Zhao

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhuocheng Xin *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qi Liu *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Dashan Ai *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Ke ChenDepartment of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Elene MariamidzeOncology and Hematology Department, Research Institute of Clinical Medicine After Academician F. Todua, Tbilisi, Georgia.
Mostafa Aziz SumonDepartment of Radiation Oncology, Kurmitola General Hospital, Dhaka, Bangladesh.
Bharti DevnaniDepartment of Radiotherapy and Oncology, All India Institute of Medical Sciences, New Delhi, India.
Rille PihlakMedical Oncology Department, St Bartholomew's Hospital, London, UK.
Hongcheng ZhuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. zhuhc90@163.com.ORCID 0000-0001-7444-5123
Kuaile ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. kuaile_z@sina.com.

Funding

Bethune Charitable Foundation flzh202119Chinese Society of Clinical Oncology Y-Young2020-0003National Natural Science Foundation of China 82102827
6 · The paper itself

Abstract

opinion statementEsophageal cancer is a global health problem, which is 7th most common and 6th most deadly cancer. It has been the era of immuno-oncology for esophageal cancer management. Radiation therapy has been one of the key local therapeutic approaches for esophageal cancer treatment, while its role in advanced disease is challenging and debatable. There have been emerging clinical and translational studies of radiation therapy in recurrent or metastatic esophageal cancer. Immunotherapy has been established the standard care of 1st and 2nd line systemic therapies of advanced esophageal cancer, and the development of tumor immunity has opened a new chapter for the esophageal cancer radiation therapy. The current review will summarize the classic radiation therapy research in advanced esophageal cancer, as well as the most recent key findings. The subtitles will cover palliative radiotherapy for dysphagia, re-radiation for recurrent disease, oligo-focal disease management and stereotactic radiation therapy, and radiotherapy with immunotherapy. Radiotherapy plays vital role in multidisciplinary management of advanced EC. External or intratumoral irradiation has been used for palliation of dysphagia and improving QOL in esophageal cancer patients traditionally, while recent clinical and technical advance enables radiotherapy to be considered in recurrent or metastatic disease for curation attention. Novel clinical and translational investigation is opening a new chapter of radiotherapy with immunotherapy for benefiting advanced EC patients.

Indexed as

Deglutition DisordersEsophageal NeoplasmsHumansPalliative CareQuality of LifeAdvanced esophageal cancerImmunotherapyOligometastasesPalliative radiotherapyRe-irradiation

Identifiers

PMID37812321

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.